Status:
COMPLETED
MCO Membrane Efficiency in Septic Shock Patients
Lead Sponsor:
Fiorenza Ferrari
Collaborating Sponsors:
International Renal Research Institute Vicenza
University of Giessen
Conditions:
Septic Shock
Acute Kidney Injury
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This is a monocentre randomized pilot study. All patients received two consecutive RRT: CVVHD with MCO filter (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration (CVVHDF) with HFF(AV...
Detailed Description
This is a monocentre randomized pilot study. All patients received CVVHD with MCO filter (Ultraflux® EMiC®2) and post-Continuous Veno-Venous Hemodiafiltration (CVVHDF) with HFF(AV1000S®) in a controll...
Eligibility Criteria
Inclusion
- Age \> 18 years;
- septic shock according to ACCP/SCCM criteria
- AKI KDIGO stage 3
- clinical decision to begin citrate based-RRT for at least 48 hours
- Hb \>= 9 g/dL
- Obtain the informed consent
Exclusion
- Pre-existing chronic renal insufficiency
- Weight \> 125 kg Life expectancy \<24 hr
- Declared do Not Resuscitate or Comfort Measures
- Platelets \< 20 \[10\^3/ul\] or active bleeding
- Pregnancy
- Contraindication to citrate
Key Trial Info
Start Date :
December 31 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04834921
Start Date
December 31 2017
End Date
January 31 2021
Last Update
April 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fiorenza Ferrari
Pavia, PV, Italy, 27000